View Older Stories View More Recent Stories
-
Form N-PX RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ex-Amazon Robotics Leaders at Reframe Systems Raise $20M to Scale Microfactories to Tackle America’s Housing Crisis
-
Invivyd closes $57.5 million public offering with full underwriter option
-
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
-
Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G ASSEMBLY BIOSCIENCES, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Verona Pharma plc Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A SUTRO BIOPHARMA, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A SERA PROGNOSTICS, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Day One Biopharmaceutica Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Boundless Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Alector, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
-
Lilly signs up to $1.3 billion deal with Superluminal for obesity drugs
-
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity
-
Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Assembly Biosciences prices $175 million equity financing with Gilead
-
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
-
Be Bio Announces First Participant Dosed in BeCoMe-9 Trial of BE-101 in Hemophilia B
-
Pahr Therapeutics Raises $14 Million Seed Financing to Pursue Innovative Treatments for Pulmonary Arterial Hypertension
-
Form SCHEDULE 13G Contineum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
RA Capital Management Announces $120 Million Planetary Health Fund
-
SAB BIO Announces Oversubscribed $175 Million Private Placement
-
Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda
-
T-knife Therapeutics Appoints Christoph Broja to its Board of Directors
-
Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
-
Vor Biopharma (VOR) Announces $175 Million Private Placement
-
Vor Bio Announces $175 Million Private Placement
-
Dignify Therapeutics Announces Jeff Welch as Chief Operating Officer
-
Form SCHEDULE 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela to Present Data Highlighting Ability of its Tissue-Agnostic Test for MRD Detection and Response Monitoring to Predict Progression and Identify Non-Responders to Immunotherapy in Solid Tumors at
-
Navigator Medicines Announces First Participants Dosed in a Phase 1b Trial of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
-
New Study Reveals Agriculture as Largest, Most Resource-Intensive Industry on Earth
-
Form SCHEDULE 13D/A iTeos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
-
Form SCHEDULE 13G/A Kura Oncology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.

